Effect of diabetes mellitus on protein-energy wasting and protein wasting in end-stage renal disease

Seminars in Dialysis

Volumn 23, Issue 2, 2010, Pages 178-184

  Noori, Nazanin ^a   Kopple, Joel D ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; HUMAN; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN CALORIE MALNUTRITION; RENAL REPLACEMENT THERAPY; RISK FACTOR; WASTING SYNDROME; COMPLICATION; DIABETIC NEPHROPATHIES; KIDNEY FAILURE, CHRONIC; PROTEIN-ENERGY MALNUTRITION;

DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC; PREVALENCE; PROTEIN-ENERGY MALNUTRITION; RENAL DIALYSIS; RISK FACTORS; WASTING SYNDROME;

EID: 77953215161     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00705.x     Document Type: Article

References (84)

1. Dukkipati R, Kopple JD. Causes and prevention of protein-energy wasting in chronic kidney failure. Semin Nephrol 2009, 29:39-49.
2. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Treviño-Becerra A, Wanner C. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008, 73:391-398.
3. Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr 2007, 26:389-399.
4. Kopple JD. McCollum Award Lecture, 1996: protein-energy malnutrition in maintenance dialysis patients. Am J Clin Nutr 1997, 65:1544-1557.
5. Mehrotra R, Kopple JD. Nutritional management of maintenance dialysis patients: why aren't we doing better? Annu Rev Nutr 2001, 21:343-379.
6. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003, 42:864-881.
7. Kopple JD, Grodstein GP, Roberts CE, Blumenkrantz MJ, Friedman EA, L'Esperance FA. Nutritional status of the diabetic patient with chronic uremia. Diabetic Renal-Retinal Syndrome 1980, 239-252. In, eds, New York, Grune & Stratton
8. Malgorzewicz S, Lichodziejewska-Niemierko M, Rutkowski B, Lysiak-Szydlowska W. Nutritional status and oxidative processes in diabetic and nondiabetic peritoneal dialysis patients. J Ren Nutr 2004, 14:242-247.
9. Pupim LB, Heimburger O, Qureshi AR, Ikizler TA, Stenvinkel P. Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int 2005, 68:2368-2374.
10. Cano NJ, Roth H, Aparicio M, Azar R, Canaud B, Chauveau P, Combe C, Fouque D, Laville M, Leverve XM. Malnutrition in hemodialysis diabetic patients: evaluation and prognostic influence. Kidney Int 2002, 62:593-601. French Study Group for Nutrition in Dialysis (FSG-ND
11. Sakkas GK, Kent-Braun JA, Doyle JW, Shubert T, Gordon P, Johansen KL. Effect of diabetes mellitus on muscle size and strength in patients receiving dialysis therapy. Am J Kidney Dis 2006, 47:862-869.
12. Kopple JD. Pathophysiology of protein-energy wasting in chronic renal failure. J Nutr 1999, 129:247S-251S.
13. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004, 80:299-307.
14. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, McAllister CJ, Alcorn H, Kopple JD, Greenland S. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant 2005, 20:1880-1888.
15. Keys A, Brozek J, Henschel A, Mickelson O, Taylor HL. The Biology of Human Starvation 1950, Minneapolis, University of Minnesota Press
16. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 2006, 11:36-41.
17. Heimburger O, Lonnqvist F, Danielsson A, Nordenstrom J, Stenvinkel P. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997, 8:1423-1430.
18. Young GA, Woodrow G, Kendall S, Oldroyd B, Turney JH, Brownjohn AM, Smith MA. Increased plasma leptin/fat ratio in patients with chronic renal failure: a cause of malnutrition? Nephrol Dial Transplant 1997, 12:2318-2323.
19. Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol 1998, 9:1080-1084.
20. Hoefle G, Saely CH, Risch L, Koch L, Schmid F, Rein P, Aczél S, Berchtold S, Drexel H. Relationship between the adipose-tissue hormone resistin and coronary artery disease. Clin Chim Acta 2007, 386:1-6.
21. Malmstrom R, Taskinen MR, Karonen SL, Yki-Jarvinen H. Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. Diabetologia 1996, 39:993-996.
22. Stenvinkel P, Lindholm B, Lonnqvist F, Katzarski K, Heimburger O. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000, 11:1303-1309.
23. Ikizler TA, Flakoll PJ, Parker RA, Hakim RM. Amino acid and albumin losses during hemodialysis. Kidney Int 1994, 46:830-837.
24. Chazot C, Shahmir E, Matias B, Laidlaw S, Kopple JD. Dialytic nutrition: provision of amino acids in dialysate during hemodialysis. Kidney Int 1997, 52:1663-1670.
25. Kopple JD, Blumenkrantz MJ, Jones MR, Moran JK, Coburn JW. Plasma amino acid levels and amino acid losses during continuous ambulatory peritoneal dialysis. Am J Clin Nutr 1982, 36:395-402.
26. Sullivan JF, Eisenstein AB. Ascorbic acid depletion during hemodialysis. JAMA 1972, 220:1697-1699.
27. Hemmeloff Andersen KE. Folic acid status of patients with chronic renal failure maintained by dialysis. Clin Nephrol 1977, 8:510-513.
28. Descombes E, Hanck AB, Fellay G. Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int 1993, 43:1319-1328.
29. Papadoyannakis NJ, Stefanidis CJ, McGeown M. The effect of the correction of metabolic acidosis on nitrogen and potassium balance of patients with chronic renal failure. Am J Clin Nutr 1984, 40:623-627.
30. Bailey JL, Wang X, England BK, Price SR, Ding X, Mitch WE. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 1996, 97:1447-1453.
31. Bergstrom J, Alvestrand A, Furst P. Plasma and muscle free amino acids in maintenance hemodialysis patients without protein malnutrition. Kidney Int 1990, 38:108-114.
32. Mehrotra R, Bross R, Wang H, Appell M, Tso L, Kopple JD. Effect of high-normal compared with low-normal arterial pH on protein balances in automated peritoneal dialysis patients. Am J Clin Nutr 2009, 90:1532-1540.
33. Fouque D. Insulin-like growth factor 1 resistance in chronic renal failure. Miner Electrolyte Metab 1996, 22:133-137.
34. Siebler T, Lopaczynski W, Terry CL, Casella SJ, Munson P, De Leon DD, Phang L, Blakemore KJ, McEvoy RC, Kelley RI. Insulin-like growth factor I receptor expression and function in fibroblasts from two patients with deletion of the distal long arm of chromosome 15. J Clin Endocrinol Metab 1995, 80:3447-3457.
35. Siew ED, Pupim LB, Majchrzak KM, Shintani A, Flakoll PJ, Ikizler TA. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007, 71:146-152.
36. Brickman AS, Coburn JW, Massry SG, Norman AW. 1,25 Dihydroxy-vitamin D3 in normal man and patients with renal failure. Ann Intern Med 1974, 80:161-168.
37. Moxley MA, Bell NH, Wagle SR, Allen DO, Ashmore J. Parathyroid hormone stimulation of glucose and urea production in isolated liver cells. Am J Physiol 1974, 227:1058-1061.
38. Kopple JD, Wang H, Casaburi R, Fournier M, Lewis MI, Taylor W, Storer TW. Exercise in maintenance hemodialysis patients induces transcriptional changes in genes favoring anabolic muscle. J Am Soc Nephrol 2007, 18:2975-2986.
39. Johansen KL, Kaysen GA, Young BS, Hung AM, da Silva M, Chertow GM. Longitudinal study of nutritional status, body composition, and physical function in hemodialysis patients. Am J Clin Nutr 2003, 77:842-846.
40. Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002, 62:301-310.
41. Kalantar-Zadeh K, Balakrishnan VS. The kidney disease wasting: inflammation, oxidative stress, and diet-gene interaction. Hemodial Int 2006, 10:315-325.
42. Meerwaldt R, Zeebregts CJ, Navis G, Hillebrands JL, Lefrandt JD, Smit AJ. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am J Kidney Dis 2009, 53:138-150.
43. Alhamdani MS. Impairment of glutathione biosynthetic pathway in uraemia and dialysis. Nephrol Dial Transplant 2005, 20:124-128.
44. Friedlander MA, Witko-Sarsat V, Nguyen AT, Wu YC, Labrunte M, Verger C, Jungers P, Descamps-Latscha B. The advanced glycation endproduct pentosidine and monocyte activation in uremia. Clin Nephrol 1996, 45:379-382.
45. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997, 51:1170-1181.
46. Pupim LB, Flakoll PJ, Majchrzak KM, Aftab Guy DL, Stenvinkel P, Ikizler TA. Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. Kidney Int 2005, 68:1857-1865.
47. Hayashino Y, Fukuhara S, Akiba T, Akizawa T, Asano Y, Saito A, Bragg-Gresham JL, Ramirez SP, Port FK, Kurokawa K. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia 2007, 50:1170-1177.
48. Prasad N, Gupta A, Sinha A, Singh A, Sharma RK, Kumar A, Kaul A. A comparison of outcomes between diabetic and nondiabetic CAPD patients in India. Perit Dial Int 2008, 28:468-476.
49. Racki S, Zaputovic L, Vujicic B, Crncević-Orlić Z, Dvornik S, Mavrić Z. Comparison of survival between diabetic and non-diabetic patients on maintenance hemodialysis: a single-centre experience. Diabetes Res Clin Pract 2007, 75:169-175.
50. Xue JL, Frazier ET, Herzog CA, Collins AJ. Association of heart disease with diabetes and hypertension in patients with ESRD. Am J Kidney Dis 2005, 45:316-323.
51. Georgopoulos S, Filis K, Vourliotakis G, Bakoyannis C, Papapetrou A, Klonaris C, Papalambros E, Bastounis E. Lower extremity bypass procedures in diabetic patients with end-stage renal disease: is it worthwhile? Nephron Clin Pract 2005, 99:c37-c41.
52. Gougeon R, Pencharz PB, Sigal RJ. Effect of glycemic control on the kinetics of whole-body protein metabolism in obese subjects with non-insulin-dependent diabetes mellitus during iso- and hypoenergetic feeding. Am J Clin Nutr 1997, 65:861-870.
53. Bennet WM, Rennie MJ. Protein anabolic actions of insulin in the human body. Diabet Med 1991, 8:199-207.
54. Ikeoka D, Krusinova E. Insulin resistance and lipid metabolism. Rev Assoc Med Bras 2009, 55:234.
55. Golay A, Munger R, Assimacopoulos-Jeannet F, Bobbioni-Harsch E, Habicht F, Felber JP. Progressive defect of insulin action on glycogen synthase in obesity and diabetes. Metabolism 2002, 51:549-553.
56. Bennet WM, Connacher AA, Jung RT, Stehle P, Rennie MJ. Effects of insulin and amino acids on leg protein turnover in IDDM patients. Diabetes 1991, 40:499-508.
57. Nair KS, Ford GC, Halliday D. Effect of intravenous insulin treatment on in vivo whole body leucine kinetics and oxygen consumption in insulin-deprived type I diabetic patients. Metabolism 1987, 36:491-495.
58. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 2004, 15:1537-1545.
59. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 2006, 17:1807-1819.
60. Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 2006, 147:4160-4168.
61. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
62. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004, 14:395-403.
63. Bailey JL, Zheng B, Hu Z, Price SR, Mitch WE. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol 2006, 17:1388-1394.
64. Wing SS, Banville D. 14-kDa ubiquitin-conjugating enzyme: structure of the rat gene and regulation upon fasting and by insulin. Am J Physiol 1994, 267:E39-E48.
65. Garlick PJ. The role of leucine in the regulation of protein metabolism. J Nutr 2005, 135:1553S-1556S.
66. Proud CG, Denton RM. Molecular mechanisms for the control of translation by insulin. Biochem J 1997, 328(Pt 2):329-341.
67. Rajan VR, Mitch WE. Muscle wasting in chronic kidney disease: the role of the ubiquitin proteasome system and its clinical impact. Pediatr Nephrol 2008, 23:527-535.
68. Luzi L, Castellino P, Simonson DC, Petrides AS, DeFronzo RA. Leucine metabolism in IDDM. Role of insulin and substrate availability. Diabetes 1990, 39:38-48.
69. De Feo P, Gaisano MG, Haymond MW. Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans. J Clin Invest 1991, 88:833-840.
70. Castellino P, Giordano M, de Pascale E, Solini A. Derangements in protein metabolism induced by type I diabetes mellitus. Miner Electrolyte Metab 1998, 24:41-46.
71. Giordano M, Castellino P, DeFronzo RA. Differential responsiveness of protein synthesis and degradation to amino acid availability in humans. Diabetes 1996, 45:393-399.
72. Charlton M, Nair KS. Protein metabolism in insulin-dependent diabetes mellitus. J Nutr 1998, 128:323S-327S.
73. Gougeon R, Morais JA, Chevalier S, Pereira S, Lamarche M, Marliss EB. Determinants of whole-body protein metabolism in subjects with and without type 2 diabetes. Diabetes Care 2008, 31:128-133.
74. Pereira S, Marliss EB, Morais JA, Chevalier S, Gougeon R. Insulin resistance of protein metabolism in type 2 diabetes. Diabetes 2008, 57:56-63.
75. Denne SC, Brechtel G, Johnson A, Liechty EA, Baron AD. Skeletal muscle proteolysis is reduced in noninsulin-dependent diabetes mellitus and is unaltered by euglycemic hyperinsulinemia or intensive insulin therapy. J Clin Endocrinol Metab 1995, 80:2371-2377.
76. Gougeon R, Pencharz PB, Marliss EB. Effect of NIDDM on the kinetics of whole-body protein metabolism. Diabetes 1994, 43:318-328.
77. Luzi L, Battezzati A, Perseghin G, Bianchi E, Terruzzi I, Spotti D, Vergani S, Secchi A, La Rocca E, Ferrari G. Combined pancreas and kidney transplantation normalizes protein metabolism in insulin-dependent diabetic-uremic patients. J Clin Invest 1994, 93:1948-1958.
78. Berkelhammer CH, Baker JP, Leiter LA, Uldall PR, Whittall R, Slater A, Wolman SL. Whole-body protein turnover in adult hemodialysis patients as measured by 13C-leucine. Am J Clin Nutr 1987, 46:778-783.
79. Nair KS. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J Clin Endocrinol Metab 1987, 64:896-901.
80. Charlton MR, Adey DB, Nair KS. Evidence for a catabolic role of glucagon during an amino acid load. J Clin Invest 1996, 98:90-99.
81. Matthews DE, Pesola G, Campbell RG. Effect of epinephrine on amino acid and energy metabolism in humans. Am J Physiol 1990, 258:E948-E956.
82. Beaufrere B, Horber FF, Schwenk WF, Marsh HM, Matthews D, Gerich JE, Haymond MW. Glucocorticosteroids increase leucine oxidation and impair leucine balance in humans. Am J Physiol 1989, 257:E712-E721.
83. Horber FF, Haymond MW. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990, 86:265-272.
84. Lim VS, Kopple JD. Protein metabolism in patients with chronic renal failure: role of uremia and dialysis. Kidney Int 2000, 58:1-10.